Compare CMRE & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMRE | IOVA |
|---|---|---|
| Founded | 1974 | 2007 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2010 | 2008 |
| Metric | CMRE | IOVA |
|---|---|---|
| Price | $15.37 | $8.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $12.00 | $9.00 |
| AVG Volume (30 Days) | 324.0K | ★ 18.5M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $47.74 |
| Revenue Next Year | N/A | $40.31 |
| P/E Ratio | $5.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.84 | $1.76 |
| 52 Week High | $18.06 | $9.36 |
| Indicator | CMRE | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 64.57 |
| Support Level | $15.16 | $3.57 |
| Resistance Level | $15.86 | $9.36 |
| Average True Range (ATR) | 0.44 | 0.60 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 73.33 | 59.17 |
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.